Kidney Fibrosis - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 93 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Kidney Fibrosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Kidney Fibrosis - Pipeline Review, H2 2014', provides an overview of the Kidney Fibrosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Kidney Fibrosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Fibrosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Fibrosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Kidney Fibrosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Kidney Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Kidney Fibrosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Kidney Fibrosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Kidney Fibrosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Kidney Fibrosis Overview 8
Therapeutics Development 9
Pipeline Products for Kidney Fibrosis - Overview 9
Pipeline Products for Kidney Fibrosis - Comparative Analysis 10
Kidney Fibrosis - Therapeutics under Development by Companies 11
Kidney Fibrosis - Therapeutics under Investigation by Universities/Institutes 13
Kidney Fibrosis - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Kidney Fibrosis - Products under Development by Companies 16
Kidney Fibrosis - Products under Investigation by Universities/Institutes 17
Kidney Fibrosis - Companies Involved in Therapeutics Development 18
BioLineRx, Ltd. 18
ProMetic Life Sciences Inc. 19
Galectin Therapeutics, Inc. 20
Raptor Pharmaceuticals Corp. 21
Paloma Pharmaceuticals, Inc. 22
Angion Biomedica Corp. 23
Tobira Therapeutics, Inc. 24
GNI Group Ltd. 25
Fibrotech Therapeutics Pty. Ltd. 26
BiOrion Technologies B.V. 27
AbbVie Inc. 28
Kidney Fibrosis - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
PBI-4050 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
F-351 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
cenicriviroc - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CGEN-856 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
cysteamine DR - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
GR-MD-02 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ANG-4011 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Galectin-3 Inhibitors - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
FT-011 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SphK2 Program - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
CT-140 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BOT-191 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
SOL-1 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Gene Therapy Targeting Angiotensin II for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
LJ-1888 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
P-007 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
KBP-7018 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
P-529 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ANG-3298 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
BRN-1889 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Kidney Fibrosis - Recent Pipeline Updates 69
Kidney Fibrosis - Dormant Projects 88
Kidney Fibrosis - Product Development Milestones 89
Featured News & Press Releases 89
Jul 05, 2013: Pharmaxis Awarded Two Arc Linkage Grants For Fibrotic Research 89
Nov 01, 2012: Concert Pharma Presents Preclinical Results Of CTP-499 At Kidney Week 2012 89
Nov 01, 2012: Prometic Life Sciences Presents Positive Data On New Anti-fibrotic Drug PBI-4419 At American Society Of Nephrology Annual Meeting 90
Oct 20, 2010: GNI Receives F351 Patent Allowance in Japan 90
Aug 26, 2010: GNI Receives F351 Patent Allowance in Canada 91
Nov 07, 2007: China Patent and Trademark Office Grants Patent for F351, GNI's Key Therapeutic Product for Liver Disease 91
Appendix 92
Methodology 92
Coverage 92
Secondary Research 92
Primary Research 92
Expert Panel Validation 92
Contact Us 93
Disclaimer 93

List of Tables
Number of Products under Development for Kidney Fibrosis, H2 2014 9
Number of Products under Development for Kidney Fibrosis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Products under Investigation by Universities/Institutes, H2 2014 17
Kidney Fibrosis - Pipeline by BioLineRx, Ltd., H2 2014 18
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2014 19
Kidney Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2014 20
Kidney Fibrosis - Pipeline by Raptor Pharmaceuticals Corp., H2 2014 21
Kidney Fibrosis - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 22
Kidney Fibrosis - Pipeline by Angion Biomedica Corp., H2 2014 23
Kidney Fibrosis - Pipeline by Tobira Therapeutics, Inc., H2 2014 24
Kidney Fibrosis - Pipeline by GNI Group Ltd., H2 2014 25
Kidney Fibrosis - Pipeline by Fibrotech Therapeutics Pty. Ltd., H2 2014 26
Kidney Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2014 27
Kidney Fibrosis - Pipeline by AbbVie Inc., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Kidney Fibrosis Therapeutics - Recent Pipeline Updates, H2 2014 69
Kidney Fibrosis - Dormant Projects, H2 2014 88